Standard of Care....Important to note that our treatment is a supplement to the standard of care! It is not as an alternate to the current standard of care! With the big data that has again been reproduced via the Euphrates trial this becomes a must have for the FDA! Look for big attention on this important treatment very soon. It is too big and important to stay under the radar any longer. Will you be surprised when the FDA gives this one the nod? It's been a long slow quiet process that is about to gain the attention of health professions and markets around the world.